StreetInsider.com News Articles

OptimizeRx names Sarah Bast as chief marketing officer

Thu, 23 Jul 2026 07:30:14 -0400

OptimizeRx Corp. (Nasdaq: OPRX) has appointed Sarah Bast as chief marketing officer, the Waltham, Massachusetts-based healthcare technology company announced July 23, 2026.

Bast brings more than two decades of pharmaceutical marketing experience to the role, with a background in point-of-care media strategy, analytics, and optimization. She most recently served as executive vice president of investment marketplace at Publicis Health Media, where she developed partnerships and solutions spanning point-of-care media, electronic health records, and telehealth.

During her career, Bast worked with life sciences companies including Lilly, Bayer, Johnson & Johnson, and AstraZeneca.

In her new role, Bast will oversee OptimizeRx's marketing strategy, brand positioning,

OptimizeRx Appoints Veteran Point of Care Marketing Leader Sarah Bast as Chief Marketing Officer

Thu, 23 Jul 2026 07:30:00 -0400

Leading pharmaceutical marketing executive joins leadership team to accelerate innovation and strengthen partnerships across the life sciences industry

WALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at key decision moments, today announced the appointment of Sarah Bast as Chief Marketing Officer. Bast brings more than two decades of pharmaceutical marketing experience to the leadership team, including deep expertise in point of care (POC) media strategy, analytics, and optimization across leading healthcare

OptimizeRx Appoints Veteran Point of Care Marketing Leader Sarah Bast as Chief Marketing Officer

Thu, 23 Jul 2026 07:30:00 -0400

Leading pharmaceutical marketing executive joins leadership team to accelerate innovation and strengthen partnerships across the life sciences industry

Form SCHEDULE 13G OptimizeRx Corp Filed by: ROYCE & ASSOCIATES LP

Wed, 22 Jul 2026 12:04:00 -0400

si-local-file:///var/storage/secattach/20260722/26800457.html

Form SCHEDULE 13G OptimizeRx Corp Filed by: ROYCE & ASSOCIATES LP

Wed, 22 Jul 2026 12:04:00 -0400

si-local-file:///var/storage/secattach/20260722/26800457.html

OptimizeRx launches CopayCue to deliver copay offers in prescribing workflow

Tue, 30 Jun 2026 07:31:45 -0400

OptimizeRx Corp. (Nasdaq: OPRX) announced the launch of CopayCue™, a product designed to deliver brand savings offers, such as copay cards and affordability resources, directly within the e-prescribing workflow at the point when a healthcare professional demonstrates intent to prescribe a specific therapy.

According to the company, CopayCue uses real-time prescribing intent data drawn from OptimizeRx's network of more than 400 electronic health record and e-prescribing platforms. The product is described as an enhancement to the company's existing Financial Assistance solution and is said to reach approximately 900,000 authenticated healthcare professionals. The solution also automatically sends savings offers to the pharmacy,

OptimizeRx Launches CopayCue™, a Next-Generation Copay Activation Solution Powered by Real-Time Prescribing Intent

Tue, 30 Jun 2026 07:30:00 -0400

Enhanced technology delivers brand savings offers directly within the prescribing workflow, when HCP intent is highest

WALTHAM, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at the most important decision points, today announced the launch of CopayCue™, designed to make brand savings offers more transparent for physicians at the point of prescribing.

CopayCue is a next-generation enhancement to OptimizeRx’s foundational Financial Assistance solution, using verified, real-time

OptimizeRx Launches CopayCue™, a Next-Generation Copay Activation Solution Powered by Real-Time Prescribing Intent

Tue, 30 Jun 2026 07:30:00 -0400

Enhanced technology delivers brand savings offers directly within the prescribing workflow, when HCP intent is highest

CopayCue is a next-generation enhancement to OptimizeRx’s foundational Financial Assistance solution, using verified, real-time

OptimizeRX (OPRX) Reiterated at Buy by Stifel as New AI Tool Launched

Mon, 29 Jun 2026 07:24:56 -0400

Stifel analyst David Grossman reiterated a Buy rating and $14.00 price target on OptimizeRX (NASDAQ: OPRX).

The analyst commented, "This week OptimizeRx launched a Natural Language Audience Builder (NLAB), an AI-powered tool designed to be embedded within both demand-side platforms (DSPs) and agency media planning platforms. NLAB pairs real-world evidence with proprietary data from OptimizeRx's EHR network so pharma and agency marketers can build and manage custom HCP audiences inside the media planning and buying platforms they already use. By connecting audience intelligence to the point-of-care in the clinical workflows, NFAB will help ensure the right messages are surfaced to providers

OptimizeRX (OPRX) Reiterated at Market Outperform by Citizens Amid Upsell Opportunity

Mon, 29 Jun 2026 04:44:37 -0400

Citizens analyst Constantine Davides reiterated a Market Outperform rating and $9.00 price target on OptimizeRX (NASDAQ: OPRX).

The analyst commented, "Management highlighted the upsell opportunity within its current biopharma footprint, with its larger relationships (those that approach $10M in annual revenue) still only representing six brands per manufacturer, on average (most large pharma clients have only contracted with OPRX for two brands). OPRX continues to advance its DSP strategy, a category that has grown to represent ~80% of industry digital spend in just a few years. Our $9 target is derived by applying a 7x multiple against our 2026 EBITDA estimate."

For

OptimizeRx Launches Natural Language Audience Builder for Life Sciences DSPs and Agency Media Planning Platforms

Thu, 25 Jun 2026 07:30:00 -0400

Patent-pending, embeddable NLAB technology enables pharma and agency marketers to build custom, verified HCP audiences using natural-language prompts

WALTHAM, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare providers (HCPs) and patients at the most important decision points, today announced the launch of its patent-pending Natural Language Audience Builder (NLAB), an AI-powered tool designed to be embedded within both demand-side platforms (DSPs) and agency media planning platforms.

NLAB combines real-world evidence with proprietary data from OptimizeRx’s best-in-class EHR network

OptimizeRx Launches Natural Language Audience Builder for Life Sciences DSPs and Agency Media Planning Platforms

Thu, 25 Jun 2026 07:30:00 -0400

Patent-pending, embeddable NLAB technology enables pharma and agency marketers to build custom, verified HCP audiences using natural-language prompts

NLAB combines real-world evidence with proprietary data from OptimizeRx’s best-in-class EHR network

OptimizeRX (OPRX) Reiterated at Market Outperform by Citizens Before Annual Forum

Thu, 25 Jun 2026 04:13:28 -0400

Citizens analyst Constantine Davides reiterated a Market Outperform rating and $9.00 price target on OptimizeRX (NASDAQ: OPRX).

The analyst commented, "We are hosting our third annual Healthcare Services Forum on June 25 in Boston. In this note we review recent financial results, our estimates, investor focus areas and valuation for the three HCIT companies in our coverage universe attending the forum: NRC Health (NRC, MO, $23 PT), OptimizeRx (OPRX, MO, $9 PT) and Healthstream (HSTM, MP). A fourth that was originally scheduled to present, Simulations Plus (SLP, MP), recently announced a go-private transaction with private equity firm Altaris and can no

NRC Health (NRC) Reiterated at Market Outperform by Citizens Ahead of Annual Forum

Thu, 25 Jun 2026 04:12:24 -0400

Citizens analyst Constantine Davides reiterated a Market Outperform rating and $23.00 price target on NRC Health (NASDAQ: NRC).

NRC Health (NRC) Reiterated at Market Outperform by Citizens Ahead of Annual Forum

Thu, 25 Jun 2026 04:12:24 -0400

Citizens analyst Constantine Davides reiterated a Market Outperform rating and $23.00 price target on NRC Health (NASDAQ: NRC).

NRC Health (NRC) Reiterated at Market Outperform by Citizens Ahead of Annual Forum

Thu, 25 Jun 2026 04:12:24 -0400

Citizens analyst Constantine Davides reiterated a Market Outperform rating and $23.00 price target on NRC Health (NASDAQ: NRC).

NRC Health (NRC) Reiterated at Market Outperform by Citizens Ahead of Annual Forum

Thu, 25 Jun 2026 04:12:24 -0400

Citizens analyst Constantine Davides reiterated a Market Outperform rating and $23.00 price target on NRC Health (NASDAQ: NRC).

Form 8-K OptimizeRx Corp For: Jun 09

Fri, 12 Jun 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260612/26640858.html

Form 8-K OptimizeRx Corp For: Jun 09

Fri, 12 Jun 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260612/26640858.html

Form 4 OptimizeRx Corp For: Jun 09 Filed by: KLEMA CATHY

Wed, 10 Jun 2026 13:45:00 -0400

si-local-file:///var/storage/secattach/20260610/26629157.html

Form 4 OptimizeRx Corp For: Jun 09 Filed by: KLEMA CATHY

Wed, 10 Jun 2026 13:45:00 -0400

si-local-file:///var/storage/secattach/20260610/26629157.html

Form 4 OptimizeRx Corp For: Jun 09 Filed by: Lang James Paul

Wed, 10 Jun 2026 13:40:00 -0400

si-local-file:///var/storage/secattach/20260610/26629135.html

Form 4 OptimizeRx Corp For: Jun 09 Filed by: Lang James Paul

Wed, 10 Jun 2026 13:40:00 -0400

si-local-file:///var/storage/secattach/20260610/26629135.html

Form 4 OptimizeRx Corp For: Jun 09 Filed by: Presti Mariyamma Varghese

Wed, 10 Jun 2026 13:39:00 -0400

si-local-file:///var/storage/secattach/20260610/26629133.html

Form 4 OptimizeRx Corp For: Jun 09 Filed by: Presti Mariyamma Varghese

Wed, 10 Jun 2026 13:39:00 -0400

si-local-file:///var/storage/secattach/20260610/26629133.html